ReviewFuture oncology (London, England)2025
Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it improves survival for heavily pretreated patients, including patients with brain metastases. Its efficacy was demonstrated in the HER2CLIMB trial and it stands as an optimal choice for patients with brain metastases, a patient population who have historically been excluded from clinical trials. Tucatinib is orally administered and has a manageable safety profile. Common adverse events include diarrhea, nausea, fatigue, and liver enzyme elevations, which are typically manageable with dose modifications and supportive care. With strong clinical efficacy and widespread approval since 2020, tucatinib remains an important treatment option for patients with HER2-positive metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.